injection

A European regulator has recommended the approval of Novo Nordisk’s Tresiba, a new basal analogue insulin for the treatment of diabetes mellitus in adults.

Marketing authorisation of the treatment could mark the first insulin approved in Europe at a higher strength than the EU-wide standard of 100 units/ml.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) backed the approval of a 200 units/ml insulin, allowing doses up to 160 units in a single injection.

Weight gain, less healthy diets and less physical activity often mean that patients may experience higher levels of insulin resistance and require insulin injections in higher doses to achieve glycaemic control, the agency said.

It is estimated that up to 700,000 diabetes patients in the EU require insulin injections of over 80 units per injection to manage their blood-sugar levels.

To minimise the risk of over- and under-dosing when using a 200 units/ml product, patients and healthcare professionals were consulted during CHMP’s evaluation of Tresiba, especially on the design of the pre-filled pen, pack design and product information.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

But, there was consensus among patients, healthcare professionals, experts and the CHMP that the introduction of a new insulin strength will require careful preparation to introduce it safely on the market.

The advisory panel of the United States Food and Drug Administration is expected to publish its recommendation of a Tresiba approval on November 8.

Image: Around 700,000 diabetes patients in the EU require insulin injections of over 80 units per injection. Photo: Courtesy of FreeDigitalPhotos.net.